Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study
- PMID: 34610047
- PMCID: PMC8491945
- DOI: 10.1371/journal.pone.0258154
Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study
Abstract
Background: The novel coronavirus disease 2019 (COVID-19) has infected 1.9% of the world population by May 2, 2021. Since most previous studies that examined risk factors for mortality and severity were based on hospitalized individuals, population-based cohort studies are called for to provide evidence that can be extrapolated to the general population. Therefore, we aimed to examine the associations of comorbidities with mortality and disease severity in individuals with COVID-19 diagnosed in 2020 in Ontario, Canada.
Methods and findings: We conducted a retrospective cohort study of all individuals with COVID-19 in Ontario, Canada diagnosed between January 15 and December 31, 2020. Cases were linked to health administrative databases maintained in the ICES which covers all residents in Ontario. The primary outcome is all-cause 30-day mortality after the first COVID-19 diagnosis, and the secondary outcome is a composite severity index containing death and hospitalization. To examine the risk factors for the outcomes, we employed Cox proportional hazards regression models and logistic regression models to adjust for demographic, socio-economic variables and comorbidities. Results were also stratified by age groups. A total of 167,500 individuals were diagnosed of COVID-19 in 2020 and included in the study. About half (43.8%, n = 73,378) had at least one comorbidity. The median follow-up period were 30 days. The most common comorbidities were hypertension (24%, n = 40,154), asthma (16%, n = 26,814), and diabetes (14.7%, n = 24,662). Individuals with comorbidity had higher risk of mortality compared to those without (HR = 2.80, 95%CI 2.35-3.34; p<0.001), and the risk substantially was elevated from 2.14 (95%CI 1.76-2.60) to 4.81 (95%CI 3.95-5.85) times as the number of comorbidities increased from one to five or more. Significant predictors for mortality included comorbidities such as solid organ transplant (HR = 3.06, 95%CI 2.03-4.63; p<0.001), dementia (HR = 1.46, 95%CI 1.35-1.58; p<0.001), chronic kidney disease (HR = 1.45, 95%CI 1.34-1.57; p<0.001), severe mental illness (HR = 1.42, 95%CI%, 1.12-1.80; p<0.001), cardiovascular disease (CVD) (HR = 1.22, 95%CI, 1.15-1.30), diabetes (HR = 1.19, 95%, 1.12-1.26; p<0.001), chronic obstructive pulmonary disease (COPD) (HR = 1.19, 95%CI 1.12-1.26; p<0.001), cancer (HR = 1.17, 95%CI, 1.09-1.27; p<0.001), hypertension (HR = 1.16, 95%CI, 1.07-1.26; p<0.001). Compared to their effect in older age groups, comorbidities were associated with higher risk of mortality and severity in individuals under 50 years old. Individuals with five or more comorbidities in the below 50 years age group had 395.44 (95%CI, 57.93-2699.44, p<0.001) times higher risk of mortality compared to those without. Limitations include that data were collected during 2020 when the new variants of concern were not predominant, and that the ICES databases do not contain detailed individual-level socioeconomic and racial variables.
Conclusion: We found that solid organ transplant, dementia, chronic kidney disease, severe mental illness, CVD, hypertension, COPD, cancer, diabetes, rheumatoid arthritis, HIV, and asthma were associated with mortality or severity. Our study highlights that the number of comorbidities was a strong risk factor for deaths and severe outcomes among younger individuals with COVID-19. Our findings suggest that in addition of prioritizing by age, vaccination priority groups should also include younger population with multiple comorbidities.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures




Similar articles
-
Cardiovascular comorbidities as predictors for severe COVID-19 infection or death.Eur Heart J Qual Care Clin Outcomes. 2021 Mar 15;7(2):172-180. doi: 10.1093/ehjqcco/qcaa081. Eur Heart J Qual Care Clin Outcomes. 2021. PMID: 33107909 Free PMC article.
-
Characteristics and outcomes of acute kidney injury in hospitalized COVID-19 patients: A multicenter study by the Turkish society of nephrology.PLoS One. 2021 Aug 10;16(8):e0256023. doi: 10.1371/journal.pone.0256023. eCollection 2021. PLoS One. 2021. PMID: 34375366 Free PMC article.
-
The anatomy of COVID-19 comorbidity networks among hospitalized Korean patients.Epidemiol Health. 2021;43:e2021035. doi: 10.4178/epih.e2021035. Epub 2021 May 7. Epidemiol Health. 2021. PMID: 33971700 Free PMC article.
-
Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis.Diabetes Obes Metab. 2020 Oct;22(10):1915-1924. doi: 10.1111/dom.14124. Epub 2020 Jul 16. Diabetes Obes Metab. 2020. PMID: 32573903 Free PMC article.
-
Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors.BMC Infect Dis. 2021 Feb 22;21(1):200. doi: 10.1186/s12879-021-05915-0. BMC Infect Dis. 2021. PMID: 33618678 Free PMC article.
Cited by
-
Assessing the effects of therapeutic combinations on SARS-CoV-2 infected patient outcomes: A big data approach.PLoS One. 2023 Mar 9;18(3):e0282587. doi: 10.1371/journal.pone.0282587. eCollection 2023. PLoS One. 2023. PMID: 36893086 Free PMC article.
-
Multimorbidity and COVID-19 in Canada: How the Pandemic Has Highlighted a Key and Yet Underappreciated Risk Factor.Can Geriatr J. 2022 Dec 1;25(4):404-406. doi: 10.5770/cgj.25.611. eCollection 2022 Dec. Can Geriatr J. 2022. PMID: 36505917 Free PMC article. No abstract available.
-
Correlates of Coronavirus Disease 2019 Inpatient Mortality at a Southern California Community Hospital With a Predominantly Hispanic/Latino Adult Population.Open Forum Infect Dis. 2023 Jan 10;10(1):ofad011. doi: 10.1093/ofid/ofad011. eCollection 2023 Jan. Open Forum Infect Dis. 2023. PMID: 36726553 Free PMC article.
-
Coronary artery calcification score as a prognostic indicator for COVID-19 mortality: evidence from a retrospective cohort study in Iran.Ann Med Surg (Lond). 2024 Apr 4;86(6):3227-3232. doi: 10.1097/MS9.0000000000001661. eCollection 2024 Jun. Ann Med Surg (Lond). 2024. PMID: 38846865 Free PMC article.
-
Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review.Int J Mol Sci. 2024 Oct 17;25(20):11149. doi: 10.3390/ijms252011149. Int J Mol Sci. 2024. PMID: 39456932 Free PMC article.
References
-
- WHO coronavirus (COVID-19) dashboard [https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=Cj...]
-
- Kontis V, Bennett JE, Rashid T, Parks RM, Pearson-Stuttard J, Guillot M, et al.: Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries. Nature Medicine 2020, 26(12):1919–1928. doi: 10.1038/s41591-020-1112-0 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical